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Abstract
Background: Human papillomaviruses (HPV) are the etiological agents of cervical cancer. The
viral E7 protein plays a crucial role in viral oncogenesis. Many strategies have been explored to
block the E7 oncoprotein activity. The single-chain variable antibody fragments (scFvs) are valuable
tools in cancer immunotherapy and can be used as "intracellular antibodies" to knock out specific
protein functions. For both in vivo and in vitro employment, the scFv intrinsic solubility and stability
are important to achieve long-lasting effects. Here we report the characterization in terms of
reactivity, solubility and thermal stability of three anti-HPV16 E7 scFvs. We have also analysed the
scFv43 sequence with the aim of improving stability and then activity of the antibody, previously
shown to have antiproliferative activity when expressed in HPV16-positive cells.
Methods: The three anti-HPV16 E7 scFv 32, 43 51 were selected from the ETH-2 "phage-display"
library. Thermal stability was evaluated with ELISA by determining the residual activity of each
purified scFv against the recombinant HPV16 E7, after incubation in the presence of human
seroalbumine for different time-intervals at different temperatures. Sequence analysis of the scFvs
was performed with BLAST and CLUSTALL programs. The scFv43 aminoacid changes were
reverted back to the consensus sequence from the immunoglobuline database by site-directed
mutagenesis. ScFv solubility was evaluated with Western blotting by determining their relative
amounts in the soluble and insoluble fractions of both prokaryotic and eukaryotic systems.
Results: ScFv51 was the most thermally stable scFv considered. Sequence analysis of the most
reactive scFv43 has evidenced 2 amino acid changes possibly involved in molecule stability, in the
VH and VL CDR3 regions respectively. By mutagenesis, two novel scFv43-derived scFvs were
obtained, scFv43 M1 and M2. ScFv43 M2 showed to have improved thermal stability and solubility
in comparison with the parental scFv43.
Conclusion: The characterization of 5 specific anti-HPV16 E7 scFvs shows features important for
their activity in vivo. ScFv43 M2 shows higher thermal stability with respect to the parental scFv43,
and scFv51 shows high stability and solubility. These properties make the 2 scFvs the best
candidates to be tested for anti-E7 activity in vivo.
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Background
Human papillomaviruses (HPVs) cause one of the most
common sexually transmitted infections in the world. A
subset of "high-risk" HPV genotypes is unequivocally
associated to cervical cancer, the second main cause of
death for cancer in women worldwide [1,2]. Nowadays
the impending commercialisation of the prophylactic
anti-HPV vaccine is shifting research efforts towards
tumour therapy. Many efforts have been made to develop
effective treatments for the HPV-associated lesions [3].
The delivery of antitumoral agents to the cervical cancer
cells may represent a valid strategy for their treatment
especially at an early lesion stage, and in addition or alter-
native to surgery of the advanced lesions.
The viral proteins E6 and E7, which play a crucial role in
viral oncogenesis [4-6] are recognised "tumor-specific
antigens" and are therefore considered suitable targets for
either immunotherapy or therapeutic vaccination against
the HPV-associated tumors [7].
Recombinant single-chain variable fragments (scFv) anti-
bodies represent powerful tools for different immuno-
therapy purposes and are particularly suitable in
intracellular immunisation to knock out specific protein
functions [8-11]. Many of them are either in clinical trial
or successfully used in therapy.
The good potential of scFvs for biomedical use is severely
limited by their intrinsic solubility and stability, which are
important characteristics to achieve long-lasting effects
both in vitro and in vivo [12]. However, it is worth noting
that the in vitro and in vivo scFv specificities are not always
comparable to one another. ScFv solubility and stability
are related to their primary structure and mostly depend
on the intrinsic ability of correctly folding by forming
intra-chain disulphide bonds in reducing environments,
in both prokaryotic and eukaryotic cells [13,14]. The scFv
thermal stability is a decisive property for their applica-
tions to targeted tumor therapy [15]. In fact the scFvs must
be stable at 37°C for many hours to be able to penetrate
into tumors, an activity that can take 12 hours or more
[16].
We have previously reported the selection of three differ-
ent scFvs (scFv 32, 43 and 51) against the E7 oncoprotein
of the HPV16 (16E7) from the ETH-2 phage display
library of human antibody fragments [17]. We have
described the antiproliferative effect of the most reactive
scFv43, when it is expressed in the nuclear and secretory
compartments of the HPV16-positive cervical carcinoma
SiHa cell line [18]. We have also demonstrated that this
effect could be specifically ascribed to inhibition of the E7
activity, in promoting cell proliferation.
In this paper we have investigated the biophysical proper-
ties of the three anti-E7 scFvs when these are expressed in
either prokaryotic or eukaryotic systems, in the attempt to
focus parameters important for their activity both in vitro
and in vivo [19].
To establish if the differences observed in the scFv stability
could be related to their secondary structure, we have
compared the scFv amino acid sequences to the consensus
sequences of both the IMGT database and the validated
intrabody database (VIDA) of intracellular stable scFvs
[20,21]. Two main non-synonymous and possibly desta-
bilizing mutations were identified in the scFv43 sequence.
A mutagenesis strategy was designed to partially revert
these mutations back to the original sequence, obtaining
2 novel antibodies, scFv43 M1 and scFv43 M2.
The 5 anti-16E7 scFvs, 2 obtained by mutagenesis and 3
originally selected, were compared to one another in
terms of thermal stability and solubility in both prokary-
otic and eukaryotic systems.
Methods
ScFvs selection
The anti-HPV16E7 scFvs were selected from the ETH-2
phage display library of human antibody fragments after
three rounds of panning in solution against the recom-
binant His-HPV16E7 protein as already described by
Accardi et al. [18].
Cloning of scFv32 and 51 sequences in scFvExpress vectors 
and plasmids
The scFv32 and 51 coding sequence were isolated from
pDN332 by NcoI/NotI restriction and subcloned into the
vectors scFvE-cyto and scFvE-nuclear, digested with the
same enzymes. For cloning into scFvE-sekdel, the encod-
ing sequences were PCR-amplified (95°C for 1 minute,
50°C for 1 minute, 74°C for 1 minute, 35 cycles) using
the SalsekD-NotsekR2 couple of primers. The sequences
of the primers used are the following (restriction sites are
underlined):
SalsekD 5'CGGCGTCGACCCGAGGTGCAGCTGGTGG 3'
NotsekR2 5'CGGCGCGGCCGCTTTGATTTCCACCTT-
GGTCCC 3'
PCR products were double-digested with SalI/NotI, gel-
purified using GFX PCR DNA and Gel Band Purification
Kit (Amersham Biosciences) and ligated into scFvE-sekdel
digested with the same enzymes. The ligation products
were used to transform competent XL1-blue E. coli cells
(Stratagene). The scFv fragments isolated with the
described procedure and cloned into the scFvExpress vec-
tors do not retain the FLAG-tag and the His-tag sequencesBMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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present in the original plasmid, and acquire a c-myc-tag at
their C-terminus, utilised for detection. The R4-cyto con-
struct expressing an anti-β-gal scFv targeted to the cyto-
plasm, utilised as a control of stable and soluble scFv
antibody, was kindly provided by A. Cattaneo.
Sequence alignments
Sequence alignments to NCBI and to VIDA were carried
out using Immunoglobulin BLAST and CLUSTALL pro-
grams.
Protein expression and purification from periplasmic and 
total extracts
The His-E7 expression and purification from the JM109 E.
coli strain and the scFv expression from the HB2151 E. coli
strain have been already described by Accardi et al. [18].
Briefly, 1 ml-aliquots of each bacterial culture were col-
lected just before isopropylthio-β-galactoside (IPTG)
induction (non induced samples), and at 2–4 hours post-
induction, pelletted and resuspended in 100 µl of 2× SDS-
loading buffer. For each sample, 20 µl-aliquots of both the
pellet and the supernatant were analysed for the scFv
expression by Western blotting followed by chemilumi-
nescence as described below. For scFv expression in the
M15 E. coli strain, an overnight (ON) culture was diluted
1: 40 in 2xTY 2%, glucose/amp (100 µg/ml)/Kan (25 µg/
ml), grown until OD600= 0.8, and centrifuged to harvest
bacteria. The pellet was recovered in 1l of 2xTY/amp/2
mM IPTG and the culture grown for 4 hours at room tem-
perature (RT). The bacteria recovered from this culture
after centrifugations were treated differently to prepare
periplasmic extract (PE) and total extract (TE). For PE
preparation, the bacteria were resuspended in 50 ml TES
(Tris-HCl pH = 7, 20% saccarose, 1 mM EDTA) in the
presence of protease inhibitors (Roche). After centrifuga-
tion at 4000 rpm for 40' at 4°C, the supernatant (PE1)
was kept at 4°C and the pellet resuspended in 50 ml of
MgSO4, shaken 10' at RT, and centrifuged at 10000 rpm
for 20' at 4°C; the supernatant (PE2) was harvested after
addition of protease inhibitors and combined to PE1,
obtaining PE. TE extracts were prepared by resuspending
the bacteria recovered from 1 litre-culture in 50 ml of lysis
buffer (50 mM Tris-HCl pH = 7, 1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 0.5 M NaCl) containing Complete
EDTA-free protease inhibitors (Roche), sonicated and
incubated for 20' on ice. After centrifugation at 12,000 g
for 10' at 4°C, supernatant (TE) was recovered and used
for the scFv purification. The scFv purification was per-
formed by affinity chromatography either on Ni-NTA
beads (Qiagen) or on protein A-Sepharose CL-4B (Amer-
sham Biosciences), according to the manufacturers'
instructions. Purity of the proteins was evaluated by
Coomassie Blue Staining after SDS-PAGE.
ScFv reactivity and affinity determination
The scFv reactivity and affinity for 16E7 were evaluated by
Western blot analysis and ELISA as already described by
Accardi et al. [18]. Briefly, the competitive ELISA for affin-
ity determination was performed by incubating in solu-
tion the purified scFvs at concentration of 0.7 µg/ml, with
His-E7 (competitor) at different concentrations in the
range 10-10 and 10-6 M, for 2 hours. The samples were then
incubated ON in microtiter wells coated with 300 ng/well
His-E7, at 4°C; the reaction was revealed by the anti-FLAG
M2 mAb (Sigma St. Louis, MO) followed by GAM-HRP
IgG (Amresco, Solon, OH) and using TMB substrate kit for
peroxidase (Vector Laboratories, Inc. Burlingame, CA)
colorimetric evaluation. The affinity constant was defined
as the reciprocal of the competitor concentration required
to reduce of the 50% the binding of the antibody not pre-
incubated with E7, and is expressed in M-1.
ScFv thermal stability
Purified scFvs were diluted in Dulbecco's PBS (DPBS) +
Ca2+  + Mg2+  containing 0.2% human serum albumin
(HSA), and incubated either at 37°C for predefined inter-
vals of time or at 40°-50°-60°C for 10'. After incubation,
the antibodies were assayed for their ability of binding the
E7 protein by ELISA. Coating of a microtiter 96-wells plate
(Nunc Polysorp) was performed ON at 4°C with purified
recombinant His-E7 at 300 ng/well in carbonate/bicarbo-
nate buffer (Pierce, Rockford, IL). The plate was saturated
with 2% NFDM and then incubated with the purified
scFvs at the desired dilutions ON at 4°C. Immunocom-
plexes were detected using the anti-FLAG M2 mAb
(Sigma, St. Louis, MO) at the dilution 1:3000, followed by
GAM-HRP IgG (Amresco, Solon, OH) as above described.
ScFv43 mutagenesis
Mutations in scFv43 were obtained by PCR amplification
of the scFv43 sequence using QuickChange™ Site-Directed
Mutagenesis Kit (Stratagene) and the following primers
(the mutated nucleotides are underlined):
43M1 5' ctgtcagcagcgtcatggtaatccggc 3'
43M1 5' gccggattaccatgacgctgctgacag 5'
43M2 5' gcagctatgccacgagctgggtccgcc 3'
43M2 5' ggcggacccagctcgtggcatagctgc 3'
The PCR reaction was performed as follows: 95°C for 30
seconds, 45°C for 1 minute; 68°C for 9 minutes, 18
cycles. The PCR products were used to transform compe-
tent DH5α cells (Stratagene). Plasmids DNA from the
obtained clones as extracted using Qiagen Spin Kit (Qia-
gen) and sequenced to confirm the incorporation of the
desired mutations. ScFv43 M1 and scFv43 M2 plasmidsBMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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were used to transform competent HB2151 cells (Strata-
gene) for scFv production.
Cell lines and transfection
The cervical epithelial tumour SiHa cell line (ATCC HTB-
35), harbouring the HPV16 genome, and the SV40-trans-
formed African green monkey kidney Cos-7 cells (ATCC
CRL 1651), were used in this study. Both the SiHa and
Cos-7 cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) containing 10% heat-inacti-
vated fetal calf serum, 100 units/ml penicillin, 100 µg/ml
streptomycin and 2 mM glutamine. Transient transfection
of 80% confluent cells was performed using the recom-
binant scFvExpress plasmids and Lipofectamine 2000
(Invitrogen) according to the manufacturer's recommen-
dations. ScFv expression in SiHa cells was analysed 48
hours post-transfection by Western blotting as described
below.
Analysis of the scFv expression
The identity of the scFvs expressed in prokaryotic systems
was evaluated after separation on SDS-PAGE and blotting
onto PVDF membrane, by Western blot analysis using the
anti-FLAG M2 monoclonal antibody (mAb; Sigma, St.
Louis, MO) as a primary antibody followed by a goat anti-
mouse horseradish peroxidase-conjugated (GAM-HRP))
IgG (Amresco, Solon, OH).
Analysis of scFv expression in eukaryotic systems was per-
formed by Western blotting after separation by SDS-PAGE
of cell lysates in 2 × SDS loading buffer and blotting onto
PVDF membrane. The rabbit anti-c-myc mAb, clone 9E10
(Sigma) was used as a primary antibody followed by a
GAR-HRP-conjugated IgG (Cappel, Amresco, Solon, OH)
incubation. The immunocomplexes were revealed by
Chemiluminescence using the Super Signal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL).
Preparation and analysis of the soluble and insoluble 
extracts
Soluble and insoluble cellular extracts were obtained as
described in ref. [11]. Briefly, a 100 mm tissue culture dish
of Cos-7 cells, transfected with each of the scFvE-cyto
recombinant vectors, was lysed with 300 µl ice-cold
extraction buffer containing containing Tris-Cl 20 mM,
pH 8, MgCl2 20 mM, 0.5% NP40, 0.1 mg/ml leupeptin,
chymostatin, and aprotinin, and 0.1 mM PMSF for 15
minutes. Cellular extracts were centrifuged at 15,000 rpm
for 15 minutes at 4°C to separate soluble (supernatant)
from insoluble proteins (pellet). Twenty µl of protein A-
Sepharose in Tris-Cl 25 mM, pH 8.6, NaCl 150 mM (TBS)
were incubated ON at 4°C with 2 µg of rabbit anti-c-myc
mAb clone 9E10, washed three times with TBS, pH 8.0,
and centrifuged for 1 minute at 1500 rpm. Three hundred
µl of the soluble pool were incubated with 20 µl of 9E10-
protein A-Sepharose for 2 hours at 4°C. The Sepharose
beads were washed four times with TBS containing 0.1%
NP40 and once with Tris-Cl 5 mM, pH 7.6. After addition
of sample buffer (Tris-Cl 125 mM, pH 6.8, SDS 1%, glyc-
erol 5%, DTT 10 mM, and bromophenol blue 0.005%),
boiling for 2 minutes, and centrifugation for 1 minute
(15,000 rpm, RT), the supernatants were loaded onto a
10% SDS-polyacrylamide gel and analysed by Western
blotting as above described.
Results
ScFvs expression, production and solubility in prokaryotic 
cells
The specific anti-16E7 scFvs 32, 43 and 51, representative
of three different groups of scFvs recently selected from
the ETH-2 library [18] were expressed in the HB2151 E.
coli strain. In inducible prokaryotic systems, the yield of
expressed product can be influenced by its gene repression
efficiency before induction. The amount of scFv 32, 43
and 51 products present in both the pellet and the culture
medium before and after IPTG induction was evaluated
by Western blotting. As shown in Fig. 1A, the scFv43
expression was quite well repressed in the non induced
culture (NI), in contrast with that of scFv32 and scFv51.
The last one was the most expressed and its production
was improved by IPTG induction. At both 2 and 4 hours
of induction all the scFvs were found in the bacterial pellet
obtained by centrifugation of the cell culture (P) and just
scFv51 was found also in the culture medium (S). As
expected, the three scFvs were released into the culture
medium after ON induction (not shown).
The amount of scFv product obtained was usually very
low, especially for scFv43, therefore different strategies
were employed to maximize the scFv expression before
purification. With the aim of efficiently repressing the scFv
32 and 51 expression in the non induced cultures, the
scFvs were expressed in the M15/Rep+ E. coli strain. This
strain carries the pREP 4 repressor plasmid inducing a
strong repression of the lacZ-promoter. A complete
repression was obtained for both the scFvs (Fig. 1B). The
expression from different colonies of each scFv clone was
analysed after IPTG induction and the best expressing col-
onies were selected and used for antibody production
(not shown). Parameters like temperature and composi-
tion of the culture medium were also considered to opti-
mise the production. IPTG induction at RT with the
addition of sorbitol to the culture medium (Materials and
Methods and ref [22]) was found to be the optimal condi-
tion for the expression of soluble scFvs.
In prokaryotic systems, the scFvs that are expressed in a
soluble form are secreted into the periplasm thanks to the
PelB leader sequence fused to their N-terminus, whereas
the scFvs that are intrinsically insoluble remain inside theBMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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Expression of scFv 32, 43 and 51 in E. coli Figure 1
Expression of scFv 32, 43 and 51 in E. coli. Panel A. Western blot analysis of lysates from cultures of the HB2151 E. coli strain 
expressing the scFv 32, 43 and 51, non induced (NI) or IPTG-induced for 2 and 4 hours at RT, before lysis. For the non induced 
cultures the total bacterial lysate was analysed, whereas pellet (P) and supernatant (S) fractions from the IPTG-induced cultures 
were utilized. Panel B. Western blot analysis of the total lysates from the M15/Rep+ E. coli strain expressing the scFv 32 and 51, 
non induced (NI) and IPTG-induced (I) for 4 hours at RT. The M15/Rep+ E. coli strain was used to repress the antibody expres-
sion in the non induced cultures. The Western blotting was performed using the anti-FLAG M2 mAb as a primary antibody, fol-
lowed by GAM-HRP incubation. The immune complexes were revealed by chemiluminescence. Molecular mass markers are 
shown on the left.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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cytoplasm. To investigate eventual differences of solubil-
ity among the scFvs, we compared the scFv amount
present in bacterial lysates (BL), which include both solu-
ble and insoluble proteins, in the periplasmic extract (PE),
and in the total extract of soluble proteins obtained after
mild lysis by sonication (TE). The Western blot analysis
clearly showed that the major part of scFv43 remained
inside the cytoplasm, while just a small amount was
secreted in the periplasm (Fig. 2A). No significant differ-
ence between the reactivities of the scFv43 extracted from
TE and PE could be revealed either in ELISA or in Western
blotting (data not shown). In contrast, scFv 32 and 51
were equally distributed between the PE and TE fractions,
showing a higher solubility of these antibody fragments
with respect to scFv43 (Fig. 2A). The Western blot analysis
demonstrated that a huge quantity of scFv51 was secreted
in the culture medium. The possibility to purify the anti-
body fragment from this fraction was then explored, but
the reactivity of the scFv obtained was 0.5-0.1 times less of
that purified from the periplasm (data not shown). These
results indicate that the highest amount of functional
antibodies was obtainable starting from TE fraction for
scFv43 [18] and from PE fraction for scFv 32 and 51.
The scFvs, carrying a His-tail fused to the C-terminus, were
purified by Ni-NTA affinity chromatography and analysed
by SDS-PAGE followed by Western blotting performed
using a mAb against the FLAG-tag positioned upstream
the His-tail. The Comassie-Blue Stained Gel analysis of all
the three purified scFvs showed a unique band with the
expected molecular weight of 27 KDa together with an
unexpected band of lower molecular mass not detectable
in Western blotting by the anti-FLAG mAb. In Fig. 2B the
results obtained using the purified scFv32 are shown. The
nature of this protein was uncertain: it may either derive
from cleavage of the FLAG-tag positioned downstream the
antibody sequence or be a contaminant His-containing
bacterial protein. To test the second hypothesis, the scFv
purification was performed by affinity chromatography
on protein A-Sepharose, a resin which can bind the DP47-
derived VH regions, bypassing the absence of the Fc region
in the antibody. The purified products exhibited high
purity indicating that the smaller protein was a bacterial
contamination (Fig. 2B, panels 3 and 4). Owing to its spe-
cificity and reliability, this procedure was then utilized for
the purification of all the three scFvs.
ScFvs thermal stability
To evaluate the scFv thermal stability, a crucial parameter
for their in vivo activity; aliquots of purified scFvs were
incubated for different intervals of time at 37°C in the
presence of HSA, simulating the in vivo environment
[23,24]. After each interval of time, the scFv residual reac-
tivity against the recombinant 16E7 protein was measured
by ELISA. The time at which the OD450 value was 50% (t1/
2) of that at time 0, was used as a parameter of thermal sta-
bility.
In Fig. 3A the OD450 values after incubation at 37°C for 15
minutes, 30 minutes, 1 hour, 2 hours and 72 hours, are
reported for each of the scFvs; it can be observed that the
t1/2 is 15 minutes for scFv32 and about 30 minutes for
scFv43, while for scFv51 the t1/2 could not be determined
because it was outside the time interval examined. Differ-
ent trends of scFv reactivity can be observed. The scFv32
reactivity halved between time 0 and 15 minutes, and
then remained stable at least up to 6 hours incubation
(data not shown); in contrast, the scFv43 reactivity was
near 0 after just 2 hours, whereas scFv51 exhibited a quite
constant OD450 value up to 72 hours.
The scFv thermal stability was also analysed by checking
the residual scFv reactivity after incubation at tempera-
tures >37°C for 10 minutes (Fig. 3B). Interestingly, the
scFv43 reactivity was reduced to 47% of the initial value
after incubation at 40°C and was almost abolished (2%)
after incubation at 50°C; the scFv32 reactivity halved at
40°C and was greatly reduced at 50°C, whereas the
scFv51 reactivity remained almost the same at 50°C and
halved just at 60°C. These results indicate scFv51 to be the
most thermally stable among the three antibody frag-
ments.
Sequence analysis
The phage display library of scFvs used in this study was
constructed from the DP47, DPL16 and DPK 22 germ line
genes. In a previous study we showed that the VH regions
of the three scFvs derived from the DP47 germ line gene
whereas the scFv 32 and 51 VL derived from the DPL16,
and the scFv43 VL from the DPK22 [18].
To investigate the presence of significant amino acid sub-
stitutions in the selected scFvs, we have compared their
nucleotidic and deduced aminoacidic sequences to the
immunoglobulin heavy chain (IGHV) consensus
sequences from the ImMunoGeneTics (IMGT) database.
The mismatchings found in the aminoacid sequences are
shown in Fig. 4 (first line of the three panels). A sense
mutation resulting in the substitution of Leucine by
Valine at position VH5 (numbering according to ref. [25])
is present in the nucleotide sequences of all the three
scFvs; a sense mutation causing the replacement of
Methionine with Threonine at position VH34 is present in
both scFv 32 and scFv43. Another sense mutation, result-
ing in the change from Asparagine to Aspartate at position
VH73, is present just in the scFv43 sequence. The last
mutation is found in 38% of the Ig VH sequences ana-
lysed by Chothia and collaborators [26] and seems not to
be relevant for the molecule stability.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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Panel A Figure 2
Panel A. Western blot analysis of scFv 32, 43 and 51 bacterial lysates (BL), periplasmic extracts (PE) and soluble total extracts 
(TE) obtained from equal volumes of bacterial culture after IPTG induction for 4 hours at RT. Panel B. Comassie-blue stained 
gel after SDS-PAGE (1 and 3) and Western blot analysis (2 and 4) of the periplasmic extract (PE) and of the purified product 
(Pur) from cultures of M15 E. coli strain expressing the scFv32 as an example. Purification was performed either by NiNTA or 
Protein A-Sepharose affinity-chromatography as indicated. The scFv detection was performed by the anti-FLAG tag M2 mAb 
followed by GAM-HRP incubation. Molecular mass markers are shown on the left.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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Looking at the scFv43 VL, an aminoacid diversity (from
Glycine to Histidine) has been found in the CDR3 at posi-
tion VL92. Of interest, this position was left unchanged
during the ETH-2 library construction as it is considered
relevant for the scFv stability [17]. Consequently, it can be
hypothesized that a mutation has arisen during the ampli-
fication cycles following the scFv selection.
The residues VH34 and VH73 belong to the 76 residues
that form the "common core" of the IgG variable domains
[26]. The residue at position 34 is part of the "common
core" buried structure, important for the conformation of
the loops in the hypervariable region. Furthermore, the
VH34 residue is included in the CDR2, which forms the
antigen-binding region together with the CDR1 and the
CDR3. The VH34 amino acid is hydrophobic in 95% of
the IgGs analysed by Chothia and collaborators. Notably,
at this position, scFvs 32 and 43 have a Threonine, a polar
residue present in just 0.1% of the sequences of the IMGT
database; therefore this amino acid could play a role in
inducing a conformational change of the scFv molecules.
Construction and characterization of the scFv43 mutants
ScFv43 has been previously shown to inhibit cell prolifer-
ation when expressed in nuclear and secretory compart-
ments but not in cell cytoplasm of the HPV16-positive
SiHa cells. We hypothesized that the lack of effect could
be ascribed either to the low amount of E7 present in the
cytoplasm or to the low stability of the antibody fragment
in this reducing environment, where it tends to form
"aggresomes" [18]. The results above reported actually
demonstrate that scFv43 is rather instable in vitro. On the
other hand, this antibody fragment is an interesting mol-
ecule because of its antiproliferative activity. In the
attempt to improve its performance by increasing stabil-
ity, the scFv43 sequence was mutated to partially revert it
back to that of the germ-line gene consensus sequences.
Utilizing a site-directed mutagenesis approach, two
scFv43 revertants were constructed: scFv43 M2 and M1. In
the scFv43 M2 sequences, the Threonine at position VH34
was replaced by a Methionine; in the scFv43 M1
sequences, the Histidine at position VL92 was replaced by
a Glycine (Fig. 4). Notably, the aminoacids restored at
positions VH34 and VL92 of the IgG consensus
sequences, are the same present at the corresponding posi-
tions in the consensus sequences for intracellular stable
antibodies of the VIDA data bank [20].
The biophysical properties of the mutants have been then
characterized and compared to those of scFv43. The reac-
tivity against the 16E7 antigen was perfectly comparable
to that of the parental scFv43 (not shown). A different
affinity could be expected particularly for scFv43 M1,
which was mutated in the CDR3 region. However, the
affinity of the two revertants was 106 M-1, in the same
range of the parental scFv43.
Solubility in bacteria and thermal stability of the rever-
tants were then analysed as above described for scFv 32,
43 and 51, and compared to those of scFv43. As shown in
Fig 5A, both scFv43 M1 and M2 were equally distributed
between the PE and TE fractions, showing solubility in the
periplasm superior to that of scFv43. In addition, Fig. 5B
shows the t1/2 of scFv43 M2 to be 24 hours, much higher
than that of scFv43 (30 minutes). In contrast, the scFv43
M1 t1/2 was 15 minutes, even lower than that of the paren-
tal scFv43. All together these results suggest that the ami-
noacid at position VH34 is involved in the scFv stability.
ScFvs intracellular expression and stability in cellular 
compartments
To examine the expression of scFv 32, 51 and 43M2 in
eukaryotic systems, the sequences encoding the three
scFvs were cloned into the vectors of the scFvExpress
(scFvE) series [27,28], which direct the expressed proteins
to different cell compartments. The vector scFvEcyto for
cytoplasmic localization does not contain any targeting
signal, the scFvEnuc contains a nuclear localization signal,
and the scFvESekdel contains both a secretory leader and
a Sekdel sequence for retention in the endoplasmic retic-
Analysis of the thermal stability of the scFv 32, 43 and 51 Figure 3
Analysis of the thermal stability of the scFv 32, 43 and 51. 
The residual anti-E7 reactivity of the scFvs was evaluated by 
ELISA after incubation at 37°C for the indicated intervals of 
time (A), and (B) at 40°-50°-60°C for 10'.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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Panel A Figure 4
Panel A. ScFv sequence alignment and mutagenesis design. The scFv 32, 43 and 51 aminoacidic sequences were aligned to the 
consensus sequences of the respective germ-line genes, namely DP47 for the VH region of the three antibodies, DPL16 for the 
VL of scFv32 and 51 and DPK22 for the VL of scFv43. The positions of the mismatching amino acids are indicated for the three 
scFvs; the numbering is according to Kabat and Wu [25]. The amino acids mutated in the scFv43M1 and M2 sequences with 
respect to that of scFv43 are in bold. Panel B. Comparison of the scFv43, 43M1 and 43M2 reactivity against E7 protein. The 
purified scFvs have been utilized at a concentration of 0.7 µg/ml in ELISA (left hand) and of 1 µg/ml in Western blotting (right 
hand). The E7 is indicated by an arrow. The immunocomplexes were revealed by anti-FLAG tag mAb followed by GAM-HRP 
incubation.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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Panel A Figure 5
Panel A. Western blot analysis of the bacterial lysates (BL), periplasmic extracts (PE) and soluble total extracts (TE) obtained 
from equal volumes of bacterial cultures expressing the scFv 43 M1 and M2 mutants, and scFv43. The Western blotting was 
performed using the anti-FLAG M2 mAb as a primary antibody, followed by GAM-HRP IgG incubation. The immunocomplexes 
were revealed by chemiluminescence. The molecular mass markers are indicated on the left. The scFv molecular weight of 
about 27.5 KDa is indicated by an arrow. Panel B. Analysis of the scFv 43 M1 and scFv43 M2 thermal stability in comparison 
with that of the parental scFv43. The scFvs were incubated at 37°C for different time intervals, indicated on the abscissa. Note 
that the scale is not linear. At the end of the incubation the residual reactivity towards the recombinant E7 protein was evalu-
ated by ELISA; the OD values at 450 nm are reported on the ordinate. The t1/2, defined as the time of halving of the anti-E7 
reactivity after incubation at 37°C, is indicated by an arrow for each scFv.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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ulum. Three recombinant plasmids were obtained for
each scFv that were used to transfect the HPV16-positive
SiHa cells.
Expression of the scFvs in these cells was monitored by
Western blotting (Fig. 6A), and their correct intracellular
localization was confirmed by immunofluorescence (data
not shown). All the three scFvs were expressed at the high-
est level in the endoplasmic reticulum, and at the lowest
level in the cytoplasm. The scFv32, 51 and 43M2 seem to
have the same expression pattern as that previously
observed for scFv43. In fact this scFv was expressed at a
high level in the secretory compartment and to a lesser
extent in the cytoplasm [18]. To examine if the scFv cyto-
plasmic low level could be related to their low solubility
in this eukaryotic environment, Cos-7 cells were trans-
fected with the different scFv constructs including the new
scFv43 M2 targeting the cytoplasm, and the scFv solubility
was analysed by cell fractioning [11]. The Cos-7 cells are
HPV-negative cells and were chosen because they can be
transfected at a higher efficiency than SiHa cells.
The scFv amount present in the soluble versus insoluble
cell fractions was analysed by Western blotting. An anti-β-
gal scFv recognized to be highly stable and soluble, R4,
was used as a control [29]. The results shown in Fig 6B
indicate that scFv43 and scFv43 M2 have the same distri-
bution between the soluble and insoluble fractions with
the larger antibody amount present in the insoluble frac-
tion. This result suggests that the revertant antibody seems
not to have acquired a better solubility compared to the
parental one. The scFv32 and 51 exhibit a totally different
pattern of solubility; the first scFv seems to be completely
insoluble, while the other one is mainly present in the sol-
uble fraction.
Discussion
In this paper we have analysed and compared the bio-
physical properties of three anti-16 E7 scFvs (scFv 32, 43
and 51) in view of their possible use in vivo for therapy of
the HPV-associated lesions. These scFvs exhibited differ-
ent yield and solubility when expressed in prokaryotic sys-
tem. ScFv43 resulted to be the least soluble, with the
major part of expressed product remaining inside the bac-
terial cell cytoplasm, and just a small amount secreted
into the periplasm. To achieve a sufficient production, dif-
ferent strategies were adopted. The scFv43 was extracted
from the total cell lysate whereas the other two antibodies
were extracted from the periplasm. The purified scFvs pro-
duced by the different procedures exhibited a good reac-
tivity against the recombinant antigen [18].
The thermal stability is a very important characteristic of
the scFvs in view of their possible use in vivo. ScFv 43 and
32 have shown the same behaviour during the first hour
of incubation at 37°C but the scFv43 was completely
loosing its reactivity during the second hour of incuba-
tion, while the scFv32 reactivity, after the initial drop,
remained stable up to 6 h. The scFv51 was the most stable
antibody fragment because maintained its initial reactiv-
ity at least up to 72 hours of incubation.
In spite of its low thermal stability, the scFv43 seemed to
work efficiently in hampering the E7 activity in the
HPV16-positive SiHa cells, as we have reported in a previ-
ous study [18]. These apparently conflicting results
prompted us to investigate the reasons of this instability.
The scFv stability depends on sequence contributions of
both the framework and the CDRs, which are responsible
for the antigen binding. Also, a mutation in one single res-
idue of the framework can play an important role in main-
taining the structure of the whole molecule [30]. Many
strategies have been adopted to improve stability of intra-
bodies for extracellular and intracellular applications [31-
33].
The comparison of the deduced scFv amino acid
sequences with both the amino acid sequences of the Igs
from the IMGT Database and the stable intracellular scFv
consensus sequences of the VIDA database [20] revealed
some mismatching. At position VH5 of all the three scFv
sequences, a sense mutation is present (Leu to Val, both
neutral amino acids, numbering according to ref. [25]).
At position VH34, scFv32 and scFv43 have a sense muta-
tion which causes a change from a neutral to a polar
amino acid (Met to Thr). ScFv43 presents additional mis-
matching at residues VH73 (Asp to Asn, both hydrophilic
amino acids) and VL92 (Gly to His, from a neutral to a
basic amino acid).
ScFv51 is the antibody fragment that shows the highest
thermal stability and this result is in agreement with the
identity of its framework sequences to the IgG sequences
from the IMGT Database.
It is interesting to note that the VH34 residue is positioned
in the Ig common core [26]. The substitution of a hydro-
phobic with a hydrophilic amino acid in this region, as is
the case of scFv32 and scFv43, may cause modifications in
the molecule conformation. However, when attempting a
correlation between the differences observed in the ther-
mal stability of these two scFvs and their amino acid
sequences, one has to consider that the VL regions of the
two scFvs are derived from different germ-line genes.
Of interest, the scFv43 amino acids at positions VH 34
and 73 are not "fitting" the consensus sequence of the
VIDA database, based on the scaffold of intrabodies with
improved solubility and expression properties in vivoBMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
Page 12 of 14
(page number not for citation purposes)
Analysis of the scFv expression in eukaryotic cells Figure 6
Analysis of the scFv expression in eukaryotic cells. Panel A. Western blot analysis of extracts from the HPV16-positive SiHa 
cells transfected with plasmids expressing the scFv 32, 43M2 and 51, targeted to the cellular cytoplasm (lane c), nucleus (lane n) 
and endoplasmic reticulum (lane er). The analysis was performed 48 hours after transfection. Non transfected cell lysates were 
used as negative control. The Western blotting was performed using the rabbit anti-c-myc mAb (clone 9E10) followed by 
GAM-HRP IgG incubation and chemiluminescence. The scFvs are indicated by arrows. To control for protein loading, the blots 
were probed with a mouse anti-actin mAb (Sigma). Panel B. Analysis of the scFv solubility. Cos-7 cells were transfected with 
plasmids expressing in the cell cytoplasm the scFv 43 (43), 43M2 (M2), 32, 51 and the highly stable and soluble R4 anti-β-gal 
scFv as a control. The cellular extracts were fractionated in soluble (lanes s) and insoluble (lanes i) fractions. The presence of 
the antibodies in these fractions was examined by Western blotting performed as above described.BMC Cancer 2007, 7:25 http://www.biomedcentral.com/1471-2407/7/25
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[20,21]. A mutagenesis strategy has been designed to pos-
sibly improve the scFv43 stability and solubility by revert-
ing the amino acids back to those present in the consensus
sequence of both the IgG and the VIDA databases. The
final aim was to improve the scFv43 intracellular perform-
ance without affecting its antigen-binding activity.
The amino acid at position VL92 resulted not to be impor-
tant for the scFv43 stability. In contrast, reverting position
VH34 seems to have fulfilled the goal, with scFv43 M2
showing improved features of thermal stability with
respect to scFv43, as assessed by the shifting of t1/2 from 30
minutes to 24 hours.
Conclusion
In summary, the specific anti-16E7 scFvs described in this
paper exhibit characteristics which are important for their
functionality in eukaryotic systems. The thermal stability
of scFv43, an antibody fragment able to contrast the E7
activity, has been improved, and we could expect scF43
M2 to function better than the parental scFv43. The
scFv51 shows a high stability, a property often more
important than affinity for the antigen in determining
intracellular behaviour and efficacy, together with a high
solubility. These properties render the two scFvs best can-
didates to be tested for anti-E7 activity in vivo.
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